Transcriptomic Biomarker Analysis – Prostate Cancer

Prostate cancer is the most common cancer in men. In-depth gene expression analysis enhances diagnosis, identifies molecular subtypes, and optimizes therapeutic decisions.

Genes Analyzed in Prostate Cancer

Our panel targets key biomarkers involved in tumor growth, aggressiveness, and treatment resistance, including:

• KLK3 (PSA) – Reference marker for screening and monitoring

• TMPRSS2-ERG – Genetic fusion present in ~50% of prostate cancers

• AR (Androgen Receptor) – Indicator of response to hormonal therapies

• PTEN – Tumor suppressor; its loss is associated with aggressive progression

• MYC – Proto-oncogene promoting cell proliferation

• NKX3.1 – Gene involved in differentiation and tumor suppression

Applications & Benefits

• Distinguishing between indolent and aggressive cancer to avoid unnecessary treatments

• Assessing resistance to hormonal therapies (Castration-Resistant Prostate Cancer - CRPC)

• Predicting post-treatment recurrence risk

• Identifying patients eligible for targeted therapies

Technologies Used

We employ advanced approaches to ensure reliable and relevant analysis:

• RT-qPCR and RNA-seq (NGS) for precise expression quantification

• Nanostring and transcriptomic arrays for multi-biomarker evaluation

• Validated genomic signatures (Decipher, Prolaris, Oncotype DX Prostate) for risk stratification

Contact us at info@genxmap.com for a personalized analysis tailored to your urological oncology projects!